SEC Filing Summary: Obalon Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. (trading symbol: OBLN) on July 24, 2019. The filing serves to report the Company's financial results for the three and six months ended June 30, 2019. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Carlsbad, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results have been reported and directs readers to a press release furnished as Exhibit 99.1 for the detailed financial data.
Material Changes
The filing does not contain specific data regarding material changes versus prior comparable periods. It solely references the issuance of a press release containing the results for the periods ended June 30, 2019.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It notes that the information furnished, including the press release, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated July 24, 2019) for actual revenue, net loss, and cash position figures.
- Verify the Company's status as an emerging growth company and any associated accounting election impacts.
- Confirm the trading symbol (OBLN) and exchange (NASDAQ Global Market) for accurate market data retrieval.
- Note that the financial details in this specific 8-K text are not incorporated by reference into other SEC filings.